These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23082976)

  • 1. Selective induction of apoptosis: promising therapy in pancreatic cancer.
    Liu Z; Li D; Zheng X; Wang E; Wang J
    Curr Pharm Des; 2013; 19(12):2259-68. PubMed ID: 23082976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth.
    Ferrari S; Severi L; Pozzi C; Quotadamo A; Ponterini G; Losi L; Marverti G; Costi MP
    Vitam Horm; 2018; 107():473-513. PubMed ID: 29544641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF-κB in the crosshairs: Rethinking an old riddle.
    Bennett J; Capece D; Begalli F; Verzella D; D'Andrea D; Tornatore L; Franzoso G
    Int J Biochem Cell Biol; 2018 Feb; 95():108-112. PubMed ID: 29277662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New targets for non-small-cell lung cancer therapy.
    Alvarez M; Roman E; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy for gastric cancer--current status.
    Kulig J; Kołodziejczyk P; Kulig P; Legutko J
    J Oncol Pharm Pract; 2013 Mar; 19(1):75-81. PubMed ID: 22711713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from Rheum officinale Baill, against pancreatic cancer in mice via inhibition of Akt activation.
    Wei WT; Chen H; Ni ZL; Liu HB; Tong HF; Fan L; Liu A; Qiu MX; Liu DL; Guo HC; Wang ZH; Lin SZ
    Int J Oncol; 2011 Dec; 39(6):1381-90. PubMed ID: 21805032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer.
    Tanaka S
    Ann Surg Oncol; 2016 Feb; 23 Suppl 2():S197-205. PubMed ID: 25749932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum.
    Gajate C; Matos-da-Silva M; Dakir el-H; Fonteriz RI; Alvarez J; Mollinedo F
    Oncogene; 2012 May; 31(21):2627-39. PubMed ID: 22056873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What's new in treatment of pancreatic cancer: a patent review (2010-2017).
    Ramos MC; Boulaiz H; Griñan-Lison C; Marchal JA; Vicente F
    Expert Opin Ther Pat; 2017 Nov; 27(11):1251-1266. PubMed ID: 28665163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges in Ras therapeutics in pancreatic cancer.
    Choi M; Bien H; Mofunanya A; Powers S
    Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
    Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
    Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer.
    Cui J; Jiang W; Wang S; Wang L; Xie K
    Curr Pharm Des; 2012; 18(17):2464-71. PubMed ID: 22372504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel targeted cancer drugs highlighted.
    Hampton T
    JAMA; 2006 Jul; 296(3):270. PubMed ID: 16849654
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular mechanisms of pancreatic cancer dissemination: the role of the chemokine system.
    Marchesi F; Grizzi F; Laghi L; Mantovani A; Allavena P
    Curr Pharm Des; 2012; 18(17):2432-8. PubMed ID: 22372498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs in the treatment of pancreatic cancer.
    Mahalingam D; Kelly KR; Swords RT; Carew J; Nawrocki ST; Giles FJ
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):311-28. PubMed ID: 19466902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy for the treatment of pancreatic cancer.
    Greenhalf W; Thomas A
    Anticancer Agents Med Chem; 2011 Jun; 11(5):418-26. PubMed ID: 21521155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
    Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
    Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The roadmap of TRAIL apoptotic pathway-targeted cancer therapies: What is next?
    Bellail AC; Hao C
    Expert Rev Anticancer Ther; 2012 May; 12(5):547-9. PubMed ID: 22594889
    [No Abstract]   [Full Text] [Related]  

  • 20. Ultra-violet irradiation induces apoptosis via mitochondrial pathway in pancreatic cancer cells.
    Yamauchi T; Adachi S; Yasuda I; Nakashima M; Kawaguchi J; Yoshioka T; Hirose Y; Kozawa O; Moriwaki H
    Int J Oncol; 2011 Dec; 39(6):1375-80. PubMed ID: 21894434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.